InsidersTradesSigma
Follow the Progyny, Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Progyny, Inc. has logged 418 public disclosures. Market capitalisation: €2bn. The latest transaction was disclosed on 4 September 2026 (Retenue fiscale). Among the most active insiders: Livingston Mark S.. The full history is accessible without an account.
418
Insider Decl.
n/a
Thresholds
€7m
3 ops.
Buy Volume
€255m
102 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Progyny, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$34.25.
25Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 12,303 of 29,062 companies
55.9
score / 100
Value51
Quality61
FCF yld9.6%
Earn yld2.9%
EV/EBITDA22.4x
ROE16%
Gross mgn24%
Net mgn4.5%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations418 total
224 shares@ US$25.66Common StockSEC:0001551306-26-000144:0
1,532 shares@ US$26.29Common StockSEC:0001551306-26-000144:1
2,244 shares@ US$31.600.0028% mcap14.7% of flowCommon StockSEC:0001551306-26-000131:1
1,193 shares@ US$31.980.0015% mcap7.9% of flowCommon StockSEC:0001551306-26-000131:0
2,244 shares@ US$31.600.0028% mcap18.9% of flowCommonSEC144:0001959173-26-005215
819 sharesCommon StockSEC:0001551306-26-000129:0
5,361 shares@ US$25.120.0054% mcap0.4% of flowCommon StockSEC:0001551306-26-000124:0
599 shares@ US$25.080.0006% mcap2.7% of flowCommonSEC144:0001959173-26-004332
2,517 shares@ US$25.500.0025% mcap2.1% of flowCommonSEC144:0001959173-26-004340
1,199 shares@ US$25.020.0012% mcap5.1% of flowCommonSEC144:0001959173-26-004285
1,530 shares@ US$25.580.0015% mcap40.4% of flowCommonSEC144:0001959173-26-004260
279 shares@ US$26.200.0003% mcap0.2% of flowCommonSEC144:0001959173-26-004250
5,660 shares0Common StockSEC:0001551306-26-000107:0
9,578 shares@ US$25.000.010% mcap100.0% of flowCommon StockSEC:0001551306-26-000071:0
4,172 shares@ US$16.980.0029% mcap22.5% of flowCommon StockSEC:0001551306-26-000059:0
3,275 shares@ US$17.42100.0% of flowCommon StockSEC:0001551306-26-000042:0
339 shares@ US$17.521.2% of flowCommon StockSEC:0001551306-26-000037:0
339 shares@ US$17.520.2% of flowCommon StockSEC:0001551306-26-000035:0
45,454 shares0Common StockSEC:0001551306-26-000032:0
28,409 shares0Common StockSEC:0001551306-26-000031:0
45,454 shares0Common StockSEC:0001551306-26-000030:0
35,228 shares0Common StockSEC:0001551306-26-000033:0
159,091 shares0Common StockSEC:0001551306-26-000029:0
2,171 shares@ US$25.680.4% of flowCommon StockSEC:0001551306-26-000006:0
6,009 shares@ US$25.680.6% of flowCommon StockSEC:0001551306-26-000004:0
25 of 418 declarations
关于 Progyny, Inc.
Progyny, Inc.（股票代码：PGNY）在美国纳斯达克市场上市。对于投资者而言，它是一家专注于生育、家庭建设和女性健康的医疗福利公司。该公司并非传统的保险公司；相反，Progyny为雇主、健康计划和其他福利购买者设计福利解决方案和临床导航服务。其平台结合了精选的供应商网络、护理协调、综合药房服务和个性化会员支持，使该公司成为员工健康福利领域一个利基但具有战略重要性的专家。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1551306/000155130625000040/pgny-20241231.htm?utm_source=openai)） Progyny最初成立于2008年，于2015年更名为Progyny, Inc.，总部位于纽约州纽约市。其企业发展与美国生育福利的增长息息相关，该类别在历史上获得的雇主和健康计划覆盖有限。随着时间的推移，Progyny在该市场建立了领先的独立专家声誉，重点关注临床结果、会员体验以及生殖专家和相关服务的简化获取。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001551306/000155130626000020/pgny-20251231.htm?utm_source=openai)） 运营方面，公司的核心收入基础集中在生育福利服务和Progyny Rx（其综合药房解决方案）上。近期，Progyny还将业务扩展到邻近领域，包括孕产妇健康、导乐服务、男性健康支持以及更广泛的女性健康解决方案，如更年期和中年护理。这种更广泛的产品组合支持了成为更全面的女性健康和家庭建设平台的战略，同时仍以其最初的生育福利利基市场为基础。（[investors.progyny.com](https://investors.progyny.com/news-releases/news-release-details/progyny-inc-announces-fourth-quarter-2025-results?utm_source=openai)） 从竞争角度来看，Progyny的主要优势在于专业化。与大型多元化保险公司和广泛的员工福利平台相比，该公司通过专注的临床模式、受管理的供应商生态系统以及以更好的护理导航为中心的专有福利设计来区分自己。该公司还强调了较高的会员满意度和有利的临床指标，这有助于支持其在大型雇主中的高端定位，这些雇主将生殖健康福利视为人才保留工具和战略性人力资源产品。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1551306/000155130625000040/pgny-20241231.htm?utm_source=openai)） 近期发展值得关注。2025年，Progyny报告了持续的收入增长，同时披露一位大客户未续约，且过渡期延长至上半年。到2026年初，该公司报告又一个强劲年份，并推出了Progyny Select，被描述为业内首个针对美国小型雇主的完全承保的补充生育和家庭建设计划。对于股票投资者而言，PGNY仍然是纳斯达克市场上以增长为导向的医疗保健服务公司，受美国就业趋势、雇主福利支出以及对生殖和女性健康解决方案的持续需求影响。（[investors.progyny.com](https://investors.progyny.com/news-releases/news-release-details/progyny-inc-announces-fourth-quarter-2025-results?utm_source=openai)）
